VDR and systemic lupus erythematosus: Treatment of MRLlpr mice with 1,25‐(OH)2D3 improved SLE symptoms, while deficiency of VDR in non‐SLE‐prone mice resulted in complement deposition within the kidney similar to mice with SLE, although with a delayed onset [215].